Antibiotic Fights Lung Transplant Complication
Posted on: Friday, 23 September 2005, 18:00 CDT
FRIDAY, Sept. 23 (HealthDay News) -- Lung transplant patients with a form of otherwise lethal, untreatable lung dysfunction may be helped by a common antibiotic, azithromycin, British researchers report.
The study of 10 male and 10 female patients found that low doses of the drug could stop and reverse lung function decline in lung transplant patients with bronchiolitis obliterans syndrome (BOS), a fatal and previously untreatable condition.
After three months of receiving 250 milligrams of azithromycin every other day, the patients showed a significant increase in lung function, as measured by a standard breathing test.
"This improvement was sustained beyond three months in the majority of patients who had initially benefited from azithromycin, as demonstrated over 11 months of follow-up," researcher Paul A. Corris, of the William Leech Centre for Lung Research at Freeman Hospital, Newcastle upon Tyne, said in a prepared statement.
The findings appear in the September issue of the American Journal of Respiratory and Critical Care Medicine.
More information
The U.S. National Library of Medicine has more about lung transplant.
SOURCE: American Thoracic Society, news release, Sept. 15, 2005~ORGT~~DRUG~
Source: HealthSCOUT
Related Articles
- Lung Cancer Alliance Hails New Mexico Proclamation on Lung Cancer Awareness Month
- November is Lung Cancer Awareness Month
- Patients With Kidney Transplants May Benefit Less From Flu Shots
- Surgeon Cleared Of Harming Patient For Organ Transplant
- New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
- Today Marks Start of Lung Cancer Awareness Month Focused on Nation's Number-One Cancer Killer
- Top German Cancer Center Delivers Advanced Gated Radiation Treatments for Lung Patients
- New Book Debuts for National Lung Cancer Awareness Month to Honor the Mother-Daughter Bond, Remember Lives Lost From the Ravages of Smoking
- Lung Cancer Awareness Month
- Recombinant Human Coagulation Factor VIIa in Jehovah's Witness Patients Undergoing Liver Transplantation
 |
 |
User Comments (0)
RSS Feeds